RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug cocktail aims to shrink head and neck tumors
Disease control OngoingThis study tests whether adding two experimental drugs (INCAGN02385 and INCAGN02390) to the immunotherapy retifanlimab can better control advanced head and neck cancer that has returned or spread. About 176 adults with PD-L1-positive tumors who have not had prior systemic therapy…
Matched conditions: RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Incyte Biosciences International Sàrl • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to reboot immune attack on head and neck cancer
Disease control OngoingThis phase 2 trial tests whether adding bavituximab to pembrolizumab can help people with advanced head and neck cancer whose tumors have stopped responding to standard immunotherapy. The study enrolled 7 participants and measures how many tumors shrink or disappear. The goal is …
Matched conditions: RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC